<DOC>
	<DOCNO>NCT00000718</DOCNO>
	<brief_summary>To determine alternate zidovudine ( AZT ) zalcitabine ( dideoxycytidine ; ddC ) ( first one ) intermittent therapy ( 1 week drug 1 week ) lessen toxic effect either drug alone , still inhibit HIV ( AIDS virus ) patient AIDS AIDS relate complex . AZT extend survival patient AIDS , AZT ddC know inhibit growth HIV . When AZT ddC give continuously prolonged period time , toxic effect occur find drug give 4 - 6 week . It hop alternate drug give one drug intermittently , toxic effect decrease without lower therapeutic effectiveness drug .</brief_summary>
	<brief_title>A Clinical Trial Alternating Intermittent Regimens 2',3'-Dideoxycytidine 3'-Azido-3'-Deoxythymidine Treatment Patients With AIDS Advanced ARC</brief_title>
	<detailed_description>AZT extend survival patient AIDS , AZT ddC know inhibit growth HIV . When AZT ddC give continuously prolonged period time , toxic effect occur find drug give 4 - 6 week . It hop alternate drug give one drug intermittently , toxic effect decrease without lower therapeutic effectiveness drug . Patients assign 1 7 treatment group . Both AZT ddC give mouth every 4 hour . One group take AZT continuously 52 week . One group alternate 1 week AZT week drug 48 week another group alternate 1 week ddC week drug 48 week . Other group alternate AZT either low-dose high-dose ddC weekly basis monthly basis 48 week . Patients see weekly first 8 week study less often thereafter . Blood sample withdraw frequently evaluate possible change immune system , toxic effect , possible change amount HIV blood . Lumbar puncture skin biopsy also perform . AMENDED : All patient receive continuous AZT switch low dose AZT already switch . This accordance result NIAID ACTG 002 , 016 , 019 demonstrate dose AZT delay progression HIV symptom .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zalcitabine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Encouraged though require : Inhaled pentamidine prophylaxis Pneumocystis carinii pneumonia ( PCP ) . Allowed : AL721 use discourage prohibit . Use aspirin , acetaminophen , nonsteroidal antiinflammatory agent minimize , continuous use &gt; 72 hour discourage . Acute therapy ( 7 day ) oral acyclovir . Acute therapy ketoconazole . Concurrent Treatment : Allowed : Up 4 unit pack red blood cell hemoglobin toxicity . All patient must follow : A consistently positive serum HIV p24 antigen = &gt; 70 pg/ml , define Abbott HIV antigen test , two occasion . The test must within 1 month study entry , separate least 72 hour , last must within 2 week start therapy . Any negative antigen test period exclude patient study . A positive antibody HIV confirm federally license ELISA test kit . Patients group A must AIDS relate complex ( ARC ) define document presence least one following : Recurrent oral candidiasis . Hairy leukoplakia . History herpes zoster . Temperature &gt; 38.5 degree C without night sweat , persist &gt; 14 consecutive day &gt; 15 day 30day interval prior study entry . Weight loss &gt; 15 lb . 10 percent body weight noted 120day period prior study entry . Diarrhea define = &gt; 3 liquid stool per day , persist &gt; 30 day prior study entry without definable cause . Patients group B must CDCdefined AIDS require systemic maintenance chemotherapy . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Transfusion dependence require 2 unit blood per month . Significant malabsorption ( &gt; 10 percent weight loss within past 3 month serum carotene &lt; 75 IU/ml vitamin A &lt; 74 IU/ml ) . Significant cardiac liver disease . Significant neurologic abnormality define one following : A significant abnormality ddC Neuropathy Targeted Symptom Questionnaire define symptom score &gt; 4 ( moderate severity ) one six category score &gt; 2 ( mild severity ) two six category . Moderate abnormality standardize neurologic exam . Any severe abnormality ( value = &gt; 4.0 ) standardize 4arm quantitative sensory test vibration threshold . Diabetes , renal failure , alcoholism . Doselimiting transfusionrequiring toxicity previous course zidovudine therapy . History idiopathic thrombocytopenic purpura . Requirement prolong acyclovir therapy . Patients group A must follow : Opportunistic infection malignancy fulfil CDC definition AIDS . Neoplasms basal cell carcinoma skin situ carcinoma cervix . Patients group B must follow : Active opportunistic infection AIDSdefining opportunistic infection require ongoing systemic therapy and/or prophylaxis inhale pentamidine Pneumocystis carinii pneumonia prophylaxis . Symptomatic visceral Kaposi 's sarcoma ( KS ) , progression KS within month prior study entry . Concurrent neoplasms KS , basal cell carcinoma skin situ carcinoma cervix . Concurrent Medication : Excluded : Neurotoxic drug . Prolonged acyclovir therapy . Antineoplastic therapy . Systemic therapy and/or prophylaxis AIDSdefining opportunistic infection , inhaled pentamidine Pneumocystis carinii pneumonia ( PCP ) prophylaxis . Other antiretroviral agent , immunomodulators , systemic corticosteroid . Other experimental medication . Concurrent Treatment : Excluded : Transfusion dependency ( require 2 unit blood per month ) . Prior Medication : Excluded : Antiretroviral agent within 60 day study entry . Biologic modifier corticosteroid within 30 day prior study entry . Dideoxycytidine ( ddC ) . Prior Treatment : Excluded : Blood transfusion within 2 week entry . Any negative HIV p24 antigen test month prior entry exclude patient study . Active drug alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Zalcitabine</keyword>
	<keyword>Dose-Response Relationship , Drug</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
</DOC>